MDMarissa Lisa Dubbelaar

Marissa Lisa Dubbelaar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marissa Lisa Dubbelaar has a total of 245 co-authors. Here are the top co-authors by number of shared publications:

  • Annika Nelde

    Cluster of Excellence iFIT (EXC2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, University of Tübingen, Tübingen, Germany

    10 shared publications
  • Juliane Stickel Walz

    Cluster of Excellence iFIT (EXC2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, University of Tübingen, Tübingen, Germany

    10 shared publications
  • Marcel Wacker

    Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany

    9 shared publications
  • Hans-Georg Rammensee

    Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany

    8 shared publications
  • Helmut Rainer Salih

    Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany

    7 shared publications
  • Jens Bauer

    Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany 2. Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Tübingen, Germany

    7 shared publications

Latest Publications

  • Open Access

    t2pmhc: A Structure-Informed Graph Neural Network to predict TCR-pMHC Binding

    by Mark Polster, Josua Stadelmaier, Elias Ball, Jonas Scheid, Jens Bauer, Annika Nelde, Manfred Claassen, Marissa Lisa Dubbelaar, Juliane Sarah Walz, Sven Nahnsen

    Mapping of T cell receptors (TCRs) to their cognate MHC-presented peptides (pMHC) is central for the development of precision immunotherapies and vaccine design. However, accurate prediction of TCR affinity to peptide antigens remains an open challenge. Most approaches rely solely on sequence information, although increasing evidence suggests that TCR-pMHC binding is primarily determined by three-dimensional structural interactions within the entire TCR-pMHC complex. Consequently, sequence-based methods often fail to generalize to peptides not included in the training data (unseen peptides). Here we introduce t2pmhc, a structure-based graph neural network framework for predicting TCR-pMHC binding using predicted structures of the entire TCR-pMHC complex. We evaluated a Graph Convolutional Network (GCN) and a Graph Attention Network, both demonstrating improved generalization to unseen peptides compared to state-of-the-art models across a variety of public datasets. Evaluation with crystallographic structures yields high-confidence predictions, indicating that current limitations of structure-based models are largely driven by the accuracy of structure prediction. Analysis of node attention patterns in t2pmhc-GCN reveals biologically consistent patterns, assigning high attention to the peptide and the CDR3 regions. Within the peptide sequence, canonical MHC anchor residues are consistently downweighted, whereas potential TCR-binding residues are upweighted. These findings establish t2pmhc as a structure-informed framework for robust TCR-pMHC binding prediction, enabling improved generalization to unseen antigens and providing a foundation for integrating TCR repertoire sequencing into vaccine design and immunotherapy.


  • Open Access

    Metabolic and transcriptional adaptations to phagocytosis sustain microglia functionality and regenerative properties

    by Mar Marquez-Ropero, Jorge Valero, Xabier Cuesta-Puente, Angel Marquez-Galera, Marta Pereira-Iglesias, Alice Louail, Marco Gonzalez-Dominguez, Sol Beccari, Luzia Lopez-Murillo, Amaia San Juan, et al.

    Phagocytosis of apoptotic cells, or efferocytosis, is a tightly regulated process that ensures tissue homeostasis and prevents mounting inflammatory responses. In the brain parenchyma, it is executed by microglia, which are encumbered by large numbers of apoptotic debris generated during development, in adult neurogenic niches, aging, and brain diseases. Emerging evidence suggest that phagocytosis is not limited to garbage disposal, but triggers adaptations in the phagocytes that may have a functional impact. To test it we developed an in vivo model of superphagocytosis induced by low cranial irradiation (LCI, 2Gy) that specifically induced apoptosis in the neurogenic niche of the adult hippocampus, synchronizing microglia in a phagocytic state within 6h and leading to full clearance by 24h. Single cell RNA sequencing and metabolomics revealed an unexpected oxidative stress in post-phagocytic microglia, accompanied by catabolic shutdown, mitochondrial remodeling, increased expression of galectin 3, and production of polyamines that led to cell death and compensatory proliferation. To test whether these changes impaired subsequent microglial phagocytosis, we used a glioblastoma model treated with sequential irradiation to induce tumor cell apoptosis. The phagocytosis efficiency of tumor-associated microglia/macrophages was comparable in the first and second apoptotic challenge, suggesting that the metabolic remodeling induced by phagocytosis was adaptive and destined to sustain their functionality. Finally, we assessed the functional impact of post-phagocytosis adaptations using galectin 3 deficient mice under LCI. We found that the recovery of the neurogenic niche after LCI strongly depended on galectin 3, demonstrating the regenerative capacity of post-phagocytic microglia. Overall, our data unveils the complexity of post-phagocytosis adaptations in microglia, underscoring their unexplored therapeutic potential in brain disorders.


  • Open Access

    PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development

    by Steffen Lemke, Marissa L Dubbelaar, Patrick Zimmermann, Jens Bauer, Annika Nelde, Naomi Hoenisch Gravel, Jonas Scheid, Marcel Wacker, Susanne Jung, Anna Dengler, et al.

    Background Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the development of personalized as well as off-the-shelf immunotherapy approaches remain challenging. Methods Over 10,000 raw mass spectrometry (MS) files from over 3,000 tissue samples were analyzed, summing to approximately seven terabytes of data. The raw MS data were processed using the standardized and open-source nf-core pipelines MHCquant2 and epitopeprediction, providing a uniform procedure for data handling. A global false discovery rate was applied to minimize false-positive identifications. Results Here, we introduce the open-access Peptides for Cancer Immunotherapy Database (PCI-DB, https://pci-db.org/), a comprehensive resource of immunopeptidome data originating from various malignant and benign primary tissues that provides the research community with a convenient tool to facilitate the identification of peptide targets for immunotherapy development. The PCI-DB includes >6.6 million HLA class I and >3.4 million HLA class II peptides from over 40 tissue types and cancer entities. First application of the database provided insights into the representation of cancer-testis antigens across malignant and benign tissues, enabling the identification and characterization of cross-tumor entity and entity-specific tumor-associated antigens (TAAs) as well as naturally presented neoepitopes from frequent cancer mutations. Further, we used the PCI-DB to design personalized peptide vaccines for two patients suffering from metastatic cancer. In a retrospective analysis, PCI-DB enabled the composition of both a multi-peptide vaccine comprising non-mutated, highly frequent TAAs matching the immunopeptidome of the individual patient’s tumor and a neoepitope-based vaccine matching the mutational profile of a patient with cancer. Both vaccine approaches induced potent and long-lasting T-cell responses, accompanied by long-term survival of these patients with advanced cancer. Conclusion The PCI-DB provides a highly versatile tool to broaden the understanding of cancer-related antigen presentation and, ultimately, supports the development of novel immunotherapies.


  • Open Access

    Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics

    by Julia Velz, Lena K. Freudenmann, Gioele Medici, Marissa Dubbelaar, Malte Mohme, David R. Ghasemi, Jonas Scheid, Daniel J. Kowalewski, Angelica B. Patterson, Anna M. Zeitlberger, et al.

    Medulloblastoma is the most frequent malignant primary brain tumor in children. Despite recent advances in integrated genomics, the prognosis in children with high-risk medulloblastoma remains devastating, and new tumor-specific therapeutic approaches are needed. Here, we present an atlas of naturally presented T cell antigens in medulloblastoma. We map the human leukocyte antigen (HLA)-presented peptidomes of 28 tumors and perform comparative immunopeptidome profiling against an in-house benign database. Medulloblastoma is shown to be a rich source of tumor-associated antigens, naturally presented on HLA class I and II molecules. Remarkably, most tumor-associated peptides and proteins are subgroup-specific, whereas shared presentation among all subgroups of medulloblastoma (WNT, SHH, Group 3 and Group 4) is rare. Functional testing of top-ranking novel candidate antigens demonstrates the induction of peptide-specific T cell responses, supporting their potential for T cell immunotherapy. This study is an in-depth mapping of naturally presented T cell antigens in medulloblastoma. Integration of immunopeptidomics, transcriptomics, and epigenetic data leads to the identification of a large set of actionable targets that can be further used for the translation into the clinical setting by facilitating the informed design of immunotherapeutic approaches to children with medulloblastoma.


  • Open Access

    PCI-DB: A novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development

    by Steffen Lemke, Marissa L. Dubbelaar, Patrick Zimmermann, Jens Bauer, Annika Nelde, Naomi Hoenisch Gravel, Jonas Scheid, Marcel Wacker, Susanne Jung, Anna Dengler, et al.

    Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the development of personalized as well as off-the-shelf immunotherapy approaches remains challenging. Here, we introduce the open-access Peptides for Cancer Immunotherapy Database (PCI-DB, https://pci-db.org/), a comprehensive resource of immunopeptidome data originating from various malignant and benign primary tissues that provides the research community with a convenient tool to facilitate the identification of peptide targets for immunotherapy development. The PCI-DB includes > 6.6 million HLA class I and > 3.4 million HLA class II peptides from over 40 tissue types and cancer entities analyzed uniformly using high-sensitive nf-core bioinformatics pipelines and applying a global peptide false discovery rate. First application of the database provided insights into the representation of cancer-testis antigens across malignant and benign tissues, enabling the identification and characterization of cross-tumor entity and entity-specific tumor-associated antigens as well as naturally presented neoepitopes from frequent cancer mutations. Further, we used the PCI-DB to design personalized peptide vaccines for two patients suffering from metastatic cancer. In a retrospective analysis, PCI-DB enabled the composition of both a multi-peptide vaccine comprising non-mutated, highly frequent tumor-associated antigens matching the immunopeptidome of the individual patient´s tumor and a neoepitope-based vaccine matching the mutational profile of a cancer patient. Both vaccine approaches induced potent and long-lasting T-cell responses, accompanied by long-term survival of these advanced cancer patients. In conclusion, the PCI-DB provides a highly versatile tool to broaden the understanding of cancer-related antigen presentation and, ultimately, supports the development of novel immunotherapies.


  • Open Access

    MHCquant2 refines immunopeptidomics tumor antigen discovery

    by Jonas Scheid, Steffen Lemke, Naomi Hoenisch-Gravel, Anna Dengler, Timo Sachsenberg, Arthur Declerq, Ralf Gabriels, Jens Bauer, Marcel Wacker, Leon Bichmann, et al.

    The identification of human leukocyte antigen (HLA)-presented peptides as targets of anti-cancer T cell response is pivotal for the development of novel immunotherapies. Mass spectrometry (MS)-based immunopeptidomics enables the detection of these peptides, yet confident identifications and thus implementation in immunotherapy design are hampered by the high diversity and low abundance of naturally presented HLA peptides. Here, we introduce MHCquant2, a Nextflow-based open-source pipeline that leverages OpenMS tools and peptide property predictors (DeepLC, MS2PIP) for highly sensitive and scalable HLA peptide identification and quantification across various MS platforms. MHCquant2 increased peptide identifications up to 27% with a significant expansion of low-abundant peptides, outperforming state-of-the-art pipelines. Using MHCquant2 we build a comprehensive benign tissue repository comprising re-analyzed data from available benign immunopeptidomes and a novel benignMHCquant2 dataset, adding more than 160,000 novel naturally presented HLA peptides. First applications of this benign repository and the MHCquant2 pipeline enabled (i) the refinement of tumor-associated antigens, (ii) the detection of novel, high-frequent tumor-exclusive peptide antigens for multiple tumor entities, and (iii) the identification and quantification of mutation-derived low-abundant neoepitopes. MHCquant2 refines tumor antigen discovery in immunopeptidomics, paving the way for the implementation of off-the-shelf and personalized immunotherapy design.


  • Open Access

    naRNA-LL37 composite DAMPs define sterile NETs as self-propagating drivers of inflammation

    by Francesca Bork, Carsten L Greve, Christine Youn, Sirui Chen, Vinicius N C Leal, Yu Wang, Berenice Fischer, Masoud Nasri, Jule Focken, Jasmin Scheurer, et al.

    Neutrophil extracellular traps (NETs) are a key antimicrobial feature of cellular innate immunity mediated by polymorphonuclear neutrophils (PMNs). NETs counteract microbes but are also linked to inflammation in atherosclerosis, arthritis, or psoriasis by unknown mechanisms. Here, we report that NET-associated RNA (naRNA) stimulates further NET formation in naive PMNs via a unique TLR8-NLRP3 inflammasome-dependent pathway. Keratinocytes respond to naRNA with expression of psoriasis-related genes (e.g., IL17, IL36 ) via atypical NOD2-RIPK signaling. In vivo, naRNA drives temporary skin inflammation, which is drastically ameliorated by genetic ablation of RNA sensing. Unexpectedly, the naRNA-LL37 ‘composite damage-associated molecular pattern (DAMP)’ is pre-stored in resting neutrophil granules, defining sterile NETs as inflammatory webs that amplify neutrophil activation. However, the activity of the naRNA-LL37 DAMP is transient and hence supposedly self-limiting under physiological conditions. Collectively, upon dysregulated NET release like in psoriasis, naRNA sensing may represent both a potential cause of disease and a new intervention target.


  • Open Access

    TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

    by Naomi Hoenisch Gravel, Annika Nelde, Jens Bauer, Lena Mühlenbruch, Sarah M. Schroeder, Marian C. Neidert, Jonas Scheid, Steffen Lemke, Marissa L. Dubbelaar, Marcel Wacker, et al.

    T cell recognition of human leukocyte antigen (HLA)-presented tumor-associated peptides is central for cancer immune surveillance. Mass spectrometry (MS)-based immunopeptidomics represents the only unbiased method for the direct identification and characterization of naturally presented tumor-associated peptides, a key prerequisite for the development of T cell-based immunotherapies. This study reports on the implementation of ion mobility separation-based time-of-flight (TOFIMS) MS for next-generation immunopeptidomics, enabling high-speed and sensitive detection of HLA-presented peptides. Applying TOFIMS-based immunopeptidomics, a novel extensive benignTOFIMS dataset was generated from 94 primary benign samples of solid tissue and hematological origin, which enabled the expansion of benign reference immunopeptidome databases with > 150,000 HLA-presented peptides, the refinement of previously described tumor antigens, as well as the identification of frequently presented self antigens and not yet described tumor antigens comprising low abundant mutation-derived neoepitopes that might serve as targets for future cancer immunotherapy development.


  • Open Access

    DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts

    by Ashish Goyal, Jens Bauer, Joschka Hey, Dimitris N. Papageorgiou, Ekaterina Stepanova, Michael Daskalakis, Jonas Scheid, Marissa Dubbelaar, Boris Klimovich, Dominic Schwarz, et al.

    Immunotherapies targeting cancer-specific neoantigens have revolutionized the treatment of cancer patients. Recent evidence suggests that epigenetic therapies synergize with immunotherapies, mediated by the de-repression of endogenous retroviral element (ERV)-encoded promoters, and the initiation of transcription. Here, we use deep RNA sequencing from cancer cell lines treated with DNA methyltransferase inhibitor (DNMTi) and/or Histone deacetylase inhibitor (HDACi), to assemble a de novo transcriptome and identify several thousand ERV-derived, treatment-induced novel polyadenylated transcripts (TINPATs). Using immunopeptidomics, we demonstrate the human leukocyte antigen (HLA) presentation of 45 spectra-validated treatment-induced neopeptides (t-neopeptides) arising from TINPATs. We illustrate the potential of the identified t-neopeptides to elicit a T-cell response to effectively target cancer cells. We further verify the presence of t-neopeptides in AML patient samples after in vivo treatment with the DNMT inhibitor Decitabine. Our findings highlight the potential of ERV-derived neoantigens in epigenetic and immune therapies.


  • Open Access

    Table of Contents

    by Raz Yirmiya, Sara Poletti, Matteo Carminati, Raffaella Zanardi, Juan Belforte, Yoel Green, Yaakov Green, Bernice Yau, David Early, Graziano Pinna, et al.